Alivus Life Sciences has announced its unaudited financial results for the third quarter and nine months ending December 31, 2025. The Board approved these results on January 22, 2026. Total Income for the quarter was ₹6,868.17 Million. Profit for the period stood at ₹1,502.61 Million. Earnings per share was reported as ₹12.25.
Financial Performance Overview
Alivus Life Sciences announced its unaudited financial results for the third quarter (Q3) and nine months ending December 31, 2025. The results were approved by the Board on January 22, 2026.
Key Financial Highlights
Here are the key highlights from the unaudited financial results:
- Total Income: For Q3 2026, Total Income reached ₹6,868.17 Million, compared to ₹6,523.00 Million for Q3 2025.
- Revenue from Operations: Q3 2026 revenue stood at ₹6,728.89 Million compared to ₹6,418.44 Million for Q3 2025.
- Profit Before Tax: For the nine-month period, the Profit Before Tax was ₹5,355.10 Million.
- Profit for the Period: The company reported a profit of ₹1,502.61 Million for Q3 2026, compared to ₹1,369.60 Million for Q3 2025.
- Earnings Per Share (EPS): Basic EPS stood at ₹12.25 for Q3 2026.
Expenses
The company also reported the following expenses:
- Cost of Materials Consumed: ₹2,763.62 Million.
- Employee Benefits Expense: ₹663.70 Million.
- Finance Costs: ₹14.94 Million.
- Depreciation and Amortisation Expense: ₹196.58 Million.
- Other Expenses: ₹988.28 Million.
Impact of New Labour Codes
The company reassessed its employee benefit obligations due to new labour codes, recognizing an incremental impact of ₹170.02 million for gratuity and ₹86.55 million for compensated absences.
Source: BSE
